Film Review - Psychedelia

A new documentary focusing on the history and science behind psychedelics titled Psychedelia is on the verge of being released soon. Sporting a compact 58-minute run-time, this film clocks in at just under an hour and it provides an easily-digestible, high-level overview of psychedelics for a wide audience, from the uninitiated square all the way to the most seasoned psychonaut.

The film opens with a moving quote that properly sets the tone:

The most beautiful and profound emotion we can experience is the sensation of the mystical. It is the sower of all true science.

-Albert Einstein

The introduction consists of a series of beautiful scenes featuring natural landscapes and voice-overs from people who healed themselves by working with psychedelics. It’s only about a minute long but it’s just enough to give the viewer a glimpse of how transformational these medicines can be when used wisely.

Following the introduction, the documentary launches into the history of psychedelics, from Albert Hofmann’s first intentional acid trip all the way up to the new wave of psychedelic research being conducted in respectable institutions like NYU and Johns Hopkins. Along the way it touches on several monumental psychedelic events, including the coining of the term “psychedelic,” R. Gordon Wasson’s encounters with Maria Sabina, the CIA’s MKUltra experiments, Tim Leary’s impact on the scene, LSD leaking out of the lab and onto the streets, and the re-emergence of psychedelic research with Rick Strassman’s DMT study.

Several experts are featured in the film, including Charles Grob, Julie Holland, Rick Doblin, Katherine MacLean, Matthew Johnson, and Ingmar Gorman. Together, their interviews help paint a complete picture of psychedelics for the audience.

In addition to talking about the psychedelics themselves, the film also gives the viewer a chance to learn more about the people working in the psychedelic field, which often turns out to be both entertaining and enlightening. One good example is Charles Grob’s story about calling his father in the middle of the night to tell him he finally knew what he wanted to do for a career—he wanted to study psychedelics. His father was supportive of Charles’ decision but also cautioned that no one would take him seriously unless he got his credentials. So he did.

Psychedelia also features interviews with a handful of participants from a psilocybin for end-of-life anxiety study that was conducted at NYU. Their personal anecdotes about how psilocybin-assisted psychotherapy helped them are moving and inspirational, and if you’re anything like me then you might shed a tear or two while listening to their stories.

Several threads are sewed together to form a coherent film: a narrative detailing the history and science of psychedelics, explanations and insights from the experts, and the moving stories from the study participants. Like any good documentary, it has a beginning, a middle, and an end, and during the final credits an epilogue provides updates on what happened to some of the people in the film, which ties things up quite nicely.

After watching the whole thing, it’s crystal clear that Psychedelia was created by an adept filmmaker—someone who has obviously put in their 10,000 hours in order to learn the skills needed to create a masterpiece of this magnitude.

That man is Pat Murphy. He started working on the documentary in 2011, when he first heard about the psilocybin for end-of-life anxiety research study at NYU. At the time he was a student at NYU Tisch School of the Arts and so, coupled with an interest in the Grateful Dead (shoutout to all the fellow Deadheads out there!), Timothy Leary, and the 1960s, he decided to begin working on the film.

I liked Psychedelia quite a bit. For one thing, it features a ton of new footage that I hadn’t seen before—and I’ve seen a lot of movies about psychedelics.

Somehow Pat was able to make grainy old footage from way back in the day (for example: scenes from a 1955 CIA film) look fresh and new. And some of the audio recordings are a delight, featuring psychedelic elders like Albert Hofmann, Allen Ginsberg, and Ralph Metzner.

One of the funniest moments in the film (which will likely be overlooked by most viewers, as it is very subtle) occurs when Rick Doblin walks upstairs to a room with lots of paperwork strewn about on a desk where a big green bong is sitting upright, ready for a nice toke.

The documentary is so well-done that it comes across as incredibly professional, which goes a long way if you’re trying to convince a skeptic in your life about the value of psychedelics. In fact, I think this is the best film to introduce people to psychedelics that will give them solid overview of psychedelic history and science. It’s a perfect documentary to show your parents, your friends, or even your therapist if you’d like them to learn more about psychedelics without inundating them with too much information all at once. It’s nicely-paced, covering a lot of ground without rushing through. All in all, it’s a solid film.

Psychedelia is definitely worth a watch whether you are completely psychedelically-naïve or you’re a highly-experienced psychonaut, and while it’s not publicly available for streaming at the time that this blog post is going live, you can sign up for the film’s newsletter to find out how to attend a virtual screening event in the near future.

Pat is partnering up with psychedelic organizations and universities to hold these online events, which include Q&A sessions with the director after the film is screened. There are two events currently on the schedule—one on February 6th with the Psychedelic Society of Minnesota and another on February 11th with the Psychedelia Integration Community that will include Katherine MacLean on the Q&A panel. There’s also an option for universities and colleges to license the film for use in the classroom.

Regardless of when you are able to get a chance to watch Psychedelia, you should definitely put it on your radar and check it out as soon as you have the opportunity. It’s rare to find a documentary that encapsulates the history and science of psychedelics this well.

Disclaimer: I received a free screening copy of this film in exchange for an honest review. However, this is not a sponsored post—all thoughts and opinions expressed here are my own.

Kevin Matthews Wants to Decriminalize Mushrooms Across Colorado

Conor McCormick-Cavanagh, writing for Westword:

Twenty months after Denver voters approved decriminalizing psychedelic mushrooms, the leader of that surprisingly successful campaign has set his sights on statewide decriminalization.

"If we’re working toward decriminalizing psilocybin and creating a regulatory model in the state of Colorado, it’s so much more effective to get it done in the legislature than to spend $5 million to $8 million on a ballot initiative and a campaign," says Kevin Matthews, the former head of Decriminalize Denver who recently registered as a Colorado lobbyist.

Matthews plans to lobby lawmakers in order to build enough support to pass a Colorado decriminalization bill by 2022, if not sooner. "If we can introduce a bill this session, then we certainly want to do that," explains Matthews, an Arvada resident and former West Point cadet. But he understands that lawmakers might not be ready for such a proposal in 2021 and, if that's the case, he says he'll focus on "building out the foundation this year, using this as an educational year, and getting in front of lawmakers."

Following on the heals of yesterday’s announcement that the newly-formed Plant Medicine Coalition is working toward the federal decriminalization of natural psychedelics, this psilocybin decriminalization attempt out of Colorado is yet more encouraging news.


New Psychedelic Reform Group Sets Its Sights on Federal Decrim

Kyle Jaeger, writing for Marijuana Moment:

The psychedelics reform movement has seen a wave of successes at the state and local level over the past couple years, but a newly formed group says the timing is right to take their activism to the next stage: Congress.

The Plant Medicine Coalition (PMC)—founded by the head of the Washington, D.C. campaign that got psychedelics decriminalization passed locally in November’s election—is a national organization that hopes to build upon what’s already been accomplished and bring the issue to Capitol Hill, in part by pushing lawmakers to approve federal funding for research into the therapeutic potential of substances like psilocybin mushrooms and ayahuasca.

They will also work to ensure the effective implementation of D.C.’s city-level policy change while supporting other local activists as they push to change laws governing natural or synthetic psychedelics.

An attempt to decriminalize psychedelics at the federal level—bravo. And what makes this even better is that the Plant Medicine Coalition is a women-led, non-profit, grassroots advocacy organization. Here’s hoping they succeed; it certainly won’t be easy.

The group’s Twitter account is brand-new but it’s worth a follow if you want to keep up-to-date with their progress.


This Week in Psychedelics - 1.22.21

ThisWeekinPsychedelics.png

Cannabis

  • France launches public consultation on legalising cannabis (France24)

  • UFC ditch marijuana ban but fighters warned to ‘temper enthusiasm’ after Usada rule change (The Independent)

  • Biden Taps Marijuana Legalization Supporter To Lead Democratic National Committee (Marijuana Moment)

  • American Medical Association Asks Court To Overturn Medical Marijuana Vote In Mississippi (Marijuana Moment)

  • Arizona: Adult Use Marijuana Sales On Track to Begin This Month (NORML)

  • This Michigan marijuana dispensary is giving free weed to anyone who got the COVID-19 vaccine (Detroit Metro Times)

  • Trump Grants Clemency To Marijuana Prisoners On Last Day In Office (Marijuana Moment)

  • Study: Nearly Half of Medical Cannabis Users Cease Using Opioids for Pain After Twelve Months (NORML)

  • Congressman Files First Federal Marijuana Reform Bill Of 2021 (Marijuana Moment)

  • Could Medical Cannabis Help with the Treatment of Movement Disorders? (Canex)

  • Latest Canadian cannabis recalls include melting vape pens, moldy bud (Marijuana Business Daily)

  • Virginia Marijuana Legalization Bill Approved By Senate Committee, With Home Cultivation Provisions Intact (Marijuana Moment)

  • “Game changer” for the sector: First cannabis company expected to list on LSE next month (Cannabis Health News)

  • Police Find 1st 'Cannabis Factory' In London's Financial District, Destroy 826 Plants (NPR)

  • Hash landing: New Zealand police ditch annual helicopter hunt for cannabis dens (The Guardian)

  • Phytol cited as potentially dangerous cannabis vape ingredient (Marijuana Business Daily)

  • Study: Cannabis Use Associated with Reduced Alcohol Intake Among Treatment-Seeking Drinkers (NORML)

  • Research establishes antibiotic potential for cannabis molecule (ScienceDaily)

  • Women who use cannabis may have harder time conceiving (Healio)

  • How Some THC Is Legal — For Now (Rolling Stone)

Magic Mushrooms

  • Florida Lawmaker Introducing Psilocybin Mushroom Legalization (Forbes)

  • Unique magic mushroom microdosing study to begin in Australia (New Atlas)

  • How Mixing Mushrooms and MDMA Affects Your Body and Brain (VICE)

  • Patient hopes Canada will introduce regulations for treatment with 'magic mushrooms' (CTV News)

  • BC Craft Supply Co Announces Letter of Intent with Psilocybin Research and Development Company Ava Pathways (Globe Newswire)

MDMA

  • MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD (Psilocybin Alpha)

Ayahuasca

5-MeO-DMT

Synthetic Cannabinoids

Ketamine

  • Ketamine Clinicians Publish Ethical Guidelines to Raise Treatment Standards (Lucid News)

  • Colorado officials resume review of ketamine program after Elijah McClain's death (CNN)

  • PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders (Psilocybin Alpha)

Miscellaneous

  • Icelandic Government Proposes Drug Decriminalisation (The Reykjavik Grapevine)

  • Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO (CNBC)

  • Psychedelic Therapy Schools Are Popping Up Like Mushrooms (Bloomberg)

  • The Biden Administration and Drug Policy: Expectation Versus Reality (Filter)

  • North American Psychedelics Index Published: Which Companies Will Be in the First Psychedelic ETF? (Psilocybin Alpha)

  • A New Supreme Court RFRA Ruling May Be a Boon to Psychedelic Religions (Chacruna)

  • Senator wants to 'lock in' 2020 drug laws (Idaho Press)

  • NeonMind Lists on the Frankfurt Stock Exchange (Psilocybin Alpha)

  • Is Psychedelic Medicine the Antidote to Anti-Black White Racism in the US? (Chacruna)

  • The Therapeutic Potential of Psychedelics and Nature Explored in New Study (Lucid News)

  • Psychedelic Authoritarianism Harm Reduction: “QAnon Shaman” Edition (Psymposia)

  • Here’s What’s Missing From Conversations About Psychedelic Integration (DoubleBlind)

  • Attorney General Merrick Garland a Disheartening Prospect (Filter)

  • Dopamine Release and Duration of Action: Rules of Thumb to Predict Addictive Potential of Phenethylamines (Spirit Pharmacist)

  • Ergot in Canada: A Lost Tradition? (Chacruna)

  • BetterLife Pharma Is Developing Second Generation Psychedelics: Drugs That Leave Out The Trip (Forbes)

  • Former Defence Force chief Chris Barrie supports increased accessibility of psychedelic drugs (The Canberra Times)

  • Could Biden Make His Country’s Global Drug War Even More Imperialist? (Filter)

  • What Will The Psychedelics Space Look Like In 2021? Experts Weigh In (Yahoo! Finance)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

Florida Lawmaker Introducing Psilocybin Mushroom Legalization

Chris Roberts, writing for Forbes:

A Florida state lawmaker plans to introduce as soon as next week a bill that would legalize psilocybin-assisted therapy in the state.

Modeled after a recent voter-approved initiative in Oregon, the proposal from State Rep. Michael Grieco, a Democrat who represents Miami Beach in the state Legislature, represents the first serious push for legal access to psilocybin on the East Coast.

It’s also the first effort to legalize magic-mushroom access in a red state, and a potential test case that could demonstrate that like cannabis legalization, access to legal psilocybin is also a bipartisan issue.

I certainly didn’t see this one coming. After all, the Southeast is not exactly a hotbed of drug policy reform. I should know—I’ve lived in North Carolina all my life.

If this bill passes Floridians would gain access to legal psilocybin therapy, as this legislation is similar to the measure that was approved in Oregon last November.